Study protocol P-MAPS: microbiome as predictor of severity in acute pancreatitis-a prospective multicentre translational study

C Ammer-Herrmenau, T Asendorf, G Beyer, S M Buchholz, S Cameron, M Damm, F Frost, R Henker, R Jaster, V Phillip, M Placzek, C Ratei, S Sirtl, T van den Berg, M J Weingarten, J Woitalla, J Mayerle, V Ellenrieder, A Neesse, C Ammer-Herrmenau, T Asendorf, G Beyer, S M Buchholz, S Cameron, M Damm, F Frost, R Henker, R Jaster, V Phillip, M Placzek, C Ratei, S Sirtl, T van den Berg, M J Weingarten, J Woitalla, J Mayerle, V Ellenrieder, A Neesse

Abstract

Background: Acute pancreatitis (AP) is an inflammatory disorder that causes a considerable economic health burden. While the overall mortality is low, around 20% of patients have a complicated course of disease resulting in increased morbidity and mortality. There is an emerging body of evidence that the microbiome exerts a crucial impact on the pathophysiology and course of AP. For several decades multiple clinical and laboratory parameters have been evaluated, and complex scoring systems were developed to predict the clinical course of AP upon admission. However, the majority of scoring systems are determined after several days and achieve a sensitivity around 70% for early prediction of severe AP. Thus, continued efforts are required to investigate reliable biomarkers for the early prediction of severity in order to guide early clinical management of AP patients.

Methods: We designed a multi-center, prospective clinical-translational study to test whether the orointestinal microbiome may serve as novel early predictor of the course, severity and outcome of patients with AP. We will recruit 400 AP patients and obtain buccal and rectal swabs within 72 h of admission to the hospital. Following DNA extraction, microbiome analysis will be performed using 3rd generation sequencing Oxford Nanopore Technologies (ONT) for 16S rRNA and metagenomic sequencing. Alpha- and beta-diversity will be determined and correlated to the revised Atlanta classification and additional clinical outcome parameters such as the length of hospital stay, number and type of complications, number of interventions and 30-day mortality.

Discussion: If AP patients show a distinct orointestinal microbiome dependent on the severity and course of the disease, microbiome sequencing could rapidly be implemented in the early clinical management of AP patients in the future.

Trial registration: ClinicalTrials.gov Identifier: NCT04777812.

Keywords: Acute pancreatitis; Biomarker; Metagenomic sequencing; Multicentric; NCT04777812; ONT; Orointestinale microbiome; Oxford nanopore technologies; P-MAPS; Prospective; Severity.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart of study protocol from enrolment to sample acquisition and correlation of sequencing results with clinical parameters

References

    1. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149:1731–1741.e3. doi: 10.1053/j.gastro.2015.08.045.
    1. Hamada S, Masamune A, Kikuta K, Hirota M, Tsuji I, Shimosegawa T. Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas. 2014;43:1244–1248. doi: 10.1097/MPA.0000000000000200.
    1. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–111. doi: 10.1136/gutjnl-2012-302779.
    1. Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ, Parks RW. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg. 2006;93:738–744. doi: 10.1002/bjs.5290.
    1. Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, et al. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include "moderately severe acute pancreatitis". Am J Gastroenterol. 2009;104:710–715. doi: 10.1038/ajg.2008.77.
    1. Buter A, Imrie CW, Carter CR, Evans S, McKay CJ. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg. 2002;89:298–302. doi: 10.1046/j.0007-1323.2001.02025.x.
    1. Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974;139:69–81.
    1. Lankisch PG, Warnecke B, Bruns D, Werner H-M, Grossmann F, Struckmann K, et al. The APACHE II score is unreliable to diagnose necrotizing pancreatitis on admission to hospital. Pancreas. 2002;24:217–222. doi: 10.1097/00006676-200204000-00002.
    1. Lankisch PG, Weber-Dany B, Hebel K, Maisonneuve P, Lowenfels AB. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. Clin Gastroenterol Hepatol. 2009;7:702–5. Doi: 10.1016/j.cgh.2009.02.020.
    1. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology. 1990;174:331–336. doi: 10.1148/radiology.174.2.2296641.
    1. Cho Y-S, Kim H-K, Jang E-C, Yeom J-O, Kim S-Y, Yu J-Y, et al. Usefulness of the Bedside Index for severity in acute pancreatitis in the early prediction of severity and mortality in acute pancreatitis. Pancreas. 2013;42:483–487. doi: 10.1097/MPA.0b013e318267c879.
    1. Buxbaum J, Quezada M, Chong B, Gupta N, Yu CY, Lane C, et al. The Pancreatitis Activity Scoring System predicts clinical outcomes in acute pancreatitis: findings from a prospective cohort study. Am J Gastroenterol. 2018;113:755–764. doi: 10.1038/s41395-018-0048-1.
    1. Ammer-Herrmenau C, Pfisterer N, Weingarten MF, Neesse A. The microbiome in pancreatic diseases: recent advances and future perspectives. United European Gastroenterol J. 2020;8:878–885. doi: 10.1177/2050640620944720.
    1. Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368:973–980. doi: 10.1126/science.aay9189.
    1. Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8:403–416. doi: 10.1158/-17-1134.
    1. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178:795–806.e12. doi: 10.1016/j.cell.2019.07.008.
    1. Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2019;574:264–267. doi: 10.1038/s41586-019-1608-2.
    1. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357:1156–1160. doi: 10.1126/science.aah5043.
    1. Wu LM, Sankaran SJ, Plank LD, Windsor JA, Petrov MS. Meta-analysis of gut barrier dysfunction in patients with acute pancreatitis. Br J Surg. 2014;101:1644–1656. doi: 10.1002/bjs.9665.
    1. Zhang XM, Zhang ZY, Zhang CH, Wu J, Wang YX, Zhang GX. Intestinal microbial community differs between acute pancreatitis patients and healthy volunteers. Biomed Environ Sci. 2018;31:81–86. doi: 10.3967/bes2018.010.
    1. Zhu Y, He C, Li X, Cai Y, Hu J, Liao Y, et al. Gut microbiota dysbiosis worsens the severity of acute pancreatitis in patients and mice. J Gastroenterol. 2019;54:347–358. doi: 10.1007/s00535-018-1529-0.
    1. Johnson CD, Besselink MG, Carter R. Acute pancreatitis. BMJ. 2014;349:g4859. doi: 10.1136/bmj.g4859.
    1. Zaheer A, Singh VK, Qureshi RO, Fishman EK. The revised Atlanta classification for acute pancreatitis: updates in imaging terminology and guidelines. Abdom Imaging. 2013;38:125–136. doi: 10.1007/s00261-012-9908-0.
    1. Kim D, Song L, Breitwieser FP, Salzberg SL. Centrifuge: rapid and sensitive classification of metagenomic sequences. Genome Res. 2016;26:1721–1729. doi: 10.1101/gr.210641.116.
    1. Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34:3094–3100. doi: 10.1093/bioinformatics/bty191.
    1. Sanderson ND, Street TL, Foster D, Swann J, Atkins BL, Brent AJ, et al. Real-time analysis of nanopore-based metagenomic sequencing from infected orthopaedic devices. BMC Genomics. 2018;19:714. doi: 10.1186/s12864-018-5094-y.
    1. Albenberg L, Esipova TV, Judge CP, Bittinger K, Chen J, Laughlin A, et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology. 2014;147:1055–63.e8. doi: 10.1053/j.gastro.2014.07.020.
    1. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635–1638. doi: 10.1126/science.1110591.
    1. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30:492–506. doi: 10.1038/s41422-020-0332-7.
    1. Araújo-Pérez F, McCoy AN, Okechukwu C, Carroll IM, Smith KM, Jeremiah K, et al. Differences in microbial signatures between rectal mucosal biopsies and rectal swabs. Gut Microbes. 2012;3:530–535. doi: 10.4161/gmic.22157.
    1. Budding AE, Grasman ME, Eck A, Bogaards JA, Vandenbroucke-Grauls CMJE, van Bodegraven AA, Savelkoul PHM. Rectal swabs for analysis of the intestinal microbiota. PLoS ONE. 2014;9:e101344. doi: 10.1371/journal.pone.0101344.
    1. Jones RB, Zhu X, Moan E, Murff HJ, Ness RM, Seidner DL, et al. Inter-niche and inter-individual variation in gut microbial community assessment using stool, rectal swab, and mucosal samples. Sci Rep. 2018;8:4139. doi: 10.1038/s41598-018-22408-4.
    1. Biehl LM, Garzetti D, Farowski F, Ring D, Koeppel MB, Rohde H, et al. Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients. PLoS ONE. 2019 doi: 10.1371/journal.pone.0215428.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner